Bałszan-Kowalska Izabela
Zakładu Biochemii Klinicznej i Diagnostyki Laboratoryjnej Instytutu Kardiologii Pomorskiej Akademii Medycznej w Szczecinie, al. Powstańców Wielkopolskich 72, 70-111 Szczecin.
Ann Acad Med Stetin. 2002;48:179-93.
Venous thromboembolism and associated complications often leading to permanent disability or death are an important problem in modern medicine. Congenital or acquired disorders of the hemostatic system, such as hypercoagulation or thrombophilia, predispose to thrombosis. The aims of the study were as follows: 1. To assess the prevalence of thrombophilia in venous thromboembolism and in healthy subjects by testing resistance to activated protein C and other markers of hemostasis; 2. To screen for factor V Leiden with a PCR-based assay; 3. To evaluate the usefulness of the adopted analytical approach for the detection of thrombophilia in clinical practice. 29 patients (17 females and 12 males) with venous thromboembolism and a history of thrombotic episodes before the age of 40, either idiopathic or associated with protracted immobilization, pregnancy or puerperium, were enrolled in the study. The control group consisted of 25 age-matched healthy subjects (14 females and 11 males) without any history of thrombosis. The following hemostatic parameters were measured: 1. Activated protein C resistance (APC-R); 2. Protein C (PC) and antithrombin III (AT III) activities; 3. Protein S (PS) activity; 4. Fibrinogen (FB) concentration; 5. Euglobin lysis time (ELT); 6. Prothrombin time (PT); 7. Activated partial thromboplastin time (APTT). The presence of Leiden mutation was detected by PCR amplification and digestion of products with Mnl 1 restrictase. The results were tested statistically using: 1. Kolmogorov-Smirnov D test; 2. Student's t-test; 3. linear regression analysis; 4. chi 2 test. The following conclusions were drawn: 1. Prevalence of thrombophilia in patients with venous thromboembolism is 31%, a figure consistent with literature data (no signs of thrombophilia were found in the control group); 2. Resistance to activated protein C is sufficient proof of Leiden mutation provided that APCR index (r) is less than 0.9 (borderline r values (0.9-1.1) require further genetic testing). 3. Methods of diagnosis of thrombophilia used in this study could be applied in routine clinical practice, the most useful ones being resistance to activated protein C, fibrinogen concentration and protein S activity. With this approach the detection of higher risk of thrombotic-embolic episodes, either acquired or inborn, is possible in most cases.
静脉血栓栓塞及其相关并发症常常导致永久性残疾或死亡,是现代医学中的一个重要问题。先天性或获得性止血系统紊乱,如高凝状态或易栓症,易引发血栓形成。本研究的目的如下:1. 通过检测对活化蛋白C的抵抗及其他止血标志物,评估静脉血栓栓塞患者和健康受试者中易栓症的患病率;2. 采用基于聚合酶链反应(PCR)的检测方法筛查凝血因子V莱顿突变;3. 评估所采用的分析方法在临床实践中检测易栓症的实用性。本研究纳入了29例静脉血栓栓塞患者(17例女性和12例男性),他们在40岁之前有血栓形成发作史,病因要么是特发性的,要么与长期制动、妊娠或产褥期有关。对照组由25名年龄匹配的健康受试者(14例女性和11例男性)组成,他们没有任何血栓形成史。测量了以下止血参数:1. 活化蛋白C抵抗(APC-R);2. 蛋白C(PC)和抗凝血酶III(AT III)活性;3. 蛋白S(PS)活性;4. 纤维蛋白原(FB)浓度;5. 优球蛋白溶解时间(ELT);6. 凝血酶原时间(PT);7. 活化部分凝血活酶时间(APTT)。通过PCR扩增并用Mnl 1限制性内切酶消化产物来检测莱顿突变的存在。使用以下方法进行统计学检验:1. 柯尔莫哥洛夫-斯米尔诺夫D检验;2. 学生t检验;3. 线性回归分析;4. 卡方检验。得出以下结论:1. 静脉血栓栓塞患者中易栓症的患病率为31%,这一数字与文献数据一致(对照组未发现易栓症迹象);2. 只要APCR指数(r)小于0.9,对活化蛋白C的抵抗就是莱顿突变的充分证据(临界r值(0.9 - 1.1)需要进一步的基因检测)。3. 本研究中使用的易栓症诊断方法可应用于常规临床实践,其中最有用的是对活化蛋白C的抵抗、纤维蛋白原浓度和蛋白S活性。通过这种方法,在大多数情况下可以检测到获得性或先天性血栓栓塞发作的较高风险。